[144] Health Catalyst, Inc SEC Filing

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) filed a Form 144 notifying the proposed sale of 3,663 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $12,317.57. The shares were acquired the same day as restricted stock from the issuer as compensation. The filing also discloses a prior sale by the same person on 06/02/2025 of 3,802 restricted shares for $13,819.51. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Routine insider sale of a small block of restricted shares; immaterial to company valuation.

The Form 144 documents a proposed sale of 3,663 shares valued at $12,317.57, representing a de minimis portion of the reported 70,373,625 shares outstanding. The shares were issued as restricted stock and listed as compensation, suggesting the transaction is part of routine insider liquidity rather than market-driven divestment. Given the small size relative to outstanding shares, this notice is unlikely to have a material impact on Health Catalyst's market capitalization or operating outlook.

Compliance Specialist

TL;DR: Filing appears complete for Rule 144 disclosure and includes required seller attestation.

The submission identifies the broker, sale date, class, acquisition date, nature of acquisition (restricted stock), and that payment was compensation. It also records a recent prior sale and includes the seller's representation about material non-public information. From a compliance perspective, the form contains the essential elements required under Rule 144 for notification of proposed sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	3663	12317.57	70373625	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Restricted Stock	Health Catalyst, Inc.			3663	09/02/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel LeSueur c/o 10897 South River From Parkway #300 South Jordan UT 84095	Restricted Stock	06/02/2025	3802	13819.51

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the HCAT Form 144 filed on 09/02/2025 disclose?

The filing discloses a proposed sale of 3,663 common shares through Morgan Stanley Smith Barney on 09/02/2025 with aggregate market value $12,317.57.

Who acquired the shares being sold in the HCAT Form 144?

The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc., and the payment type is listed as compensation.

Has the seller made other recent sales of HCAT securities?

Yes. The filing notes a prior sale on 06/02/2025 of 3,802 restricted shares for $13,819.51 by Daniel LeSueur.

How large is the proposed sale relative to shares outstanding?

The proposed sale of 3,663 shares is small compared with the reported 70,373,625 shares outstanding.

Does the Form 144 include a seller attestation about material non-public information?

Yes. The person for whose account the securities are to be sold represents they do not know any material adverse information about the issuer that has not been publicly disclosed.